Document is current

Article History

Received: 16 December 2025

Accepted: 28 May 2026

First Online: 16 June 2026

Competing interests

: A.H. was a member of the advisory boards of Axunio, Boehringer-Ingelheim, Lundbeck, Janssen, Otsuka, Rovi, Recordati, Teva and received paid speakership by these companies as well as by AbbVie and Advanz. He is the editor of the German schizophrenia guideline. S.L. has received honoraria for advising, consulting, and for lectures and/or for educational material from Angelini, Apsen, Boehringer Ingelheim, Eisai, Ekademia, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Mitsubishi, Neurotorium, Otsuka, Novo Nordisk, Recordati, Rovi, and Teva. W.S. has received a paid speakership from Mag & More (Neurocare), Recordati, Boehringer Ingelheim, and Rovi. He was a member of an advisory board of Recordati and Rovi. E.W. was a member of the advisory boards of Recordati and Boehringer-Ingelheim. S.H. has accepted speaker honoraria from Johnson & Johnson, Boehringer-Ingelheim, Recordati and Otsuka/Lundbeck; services as consultant in clinical trials were provided for the companies TEVA, ROVI, Merck und Boehringer-Ingelheim. I.M. received speaker fees from Boehringer-Ingelheim. Maximilian Hansbauer is a member of the sounding board of Rovi. Berthold Langguth was a member of the sounding board of Rovi, has received speaker honoraria from Rovi, ad contributed to the German schizophrenia guideline. SK Greiner is an advisor to the GOLDKIND Foundation. M.W. and M.R. report a relationship with Systasy Bioscience GmbH that includes employment and equity or stocks. B.D. reports a relationship with Node Biosciences, Inc that includes employment and equity or stocks. P.F. was co-editor of the German (DGPPN) schizophrenia treatment guidelines, and co-author of the WFSBP schizophrenia treatment guidelines. He was on advisory boards and received speaker fees from Janssen, Lundbeck, Otsuka, Servier, and Richter. All other authors have no competing interests to declare.